Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ICAM1 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DQA1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DQ alpha 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DQA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DPB1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DP beta 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DPB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DPA1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DP alpha 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DPA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DOB Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DO beta chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DOB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DOA Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DO alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DOA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DMB Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DM beta chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DMB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-DMA Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DM alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DMA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-C Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, C alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-B Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, B alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HLA-A Biologics Sequence Review Report 2026: HLA class I histocompatibility antigen, A alpha chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HAVCR1 Biologics Sequence Review Report 2026: Hepatitis A virus cellular receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HAVCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.